LivaNova PLC (FRA:LIA)
| Market Cap | 3.04B +80.4% |
| Revenue (ttm) | 1.18B +10.7% |
| Net Income | -206.51M |
| EPS | -3.79 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | 15.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 56.00 |
| Previous Close | 55.00 |
| Day's Range | 56.00 - 56.00 |
| 52-Week Range | 30.80 - 59.50 |
| Beta | n/a |
| RSI | 51.06 |
| Earnings Date | May 6, 2026 |
About LivaNova
LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products, therapies, and services in the United States, the United Kingdom, Germany, France, Italy, the Netherlands, Spain, Belgium, Poland, Sweden, Switzerland, Austria, Norway, Portugal, Finland, Denmark, and internationally. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing sy... [Read more]
News
Annals of Internal Medicine Publishes 12-Month Results from LivaNova's OSPREY Clinical Study for Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the journal Annals of Internal Medicine has published an article...
LivaNova to Announce First-Quarter 2026 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, ...
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the U.S. Food and Drug Administration (FDA) granted premarket approva...
LivaNova Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported fourth-quarter and full-year 2025 results and issued full-year 2026 gui...
LivaNova to Announce Fourth-Quarter and Full-Year 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its fourth-quarter and full-year 2025 results o...
LivaNova to Present at J.P. Morgan Healthcare Conference in January
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present at the J.P. Morgan 44th Annual Healthcare Conference i...
LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it will present eight posters at the American Epilepsy Society (A...
LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Ob...
LivaNova to Present at Piper Sandler Healthcare Conference in December
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general...
LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services
LONDON--(BUSINESS WIRE)---- $LIVN #epilepsy--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) assi...
LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic roadmap a...
LivaNova Reports Third-Quarter 2025 Results; Raises 2025 Guidance
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2025 and raised full-...
LivaNova to Present at Wolfe Research Healthcare Conference in November
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex Shvartsbur...
LivaNova to Announce Third-Quarter 2025 Results
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its third-quarter 2025 results on Wed., Nov. 5,...
LivaNova to Present Scientific Data at International Surgical Sleep Society 2025 Annual Meeting
LONDON--(BUSINESS WIRE)---- $LIVN #livn--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced its participation in the International Surgical Sleep Society (ISSS) ...
LivaNova Appoints Donald Zurbay as a New Director
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced the appointment of Donald (Don) Zurbay to the Company's Board of ...
LivaNova to Host Investor Day on November 12, 2025
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC announced it will host an Investor Day and product showcase on Wed., Nov. 12, 2025.
LivaNova to Present at Baird and Morgan Stanley Global Healthcare Conferences in September
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Vladimir Makatsaria, Chief Executive Officer, and Alex...
LivaNova Launches Essenz Perfusion System in China
LONDON--(BUSINESS WIRE)---- $LIVN #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced it initiated the commercial launch of the Essenz™ Perfusion...
LivaNova Reports Second-Quarter 2025 Results; Raises 2025 Guidance
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC reported results for the second quarter ended June 30, 2025, and raised full-year 2025 guidance.
LivaNova to Announce Second-Quarter 2025 Results
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its second-quarter 2025 results on Wed., Aug...
CORE-VNS Study Further Validates Effectiveness of LivaNova's VNS Therapy on Severe Focal Seizures in Both Children and Adults with Drug-Resistant Epilepsy
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced completion of the CORE-VNS study further validating effectiveness of VNS Therapy for severe focal seizures in children & adults.
LivaNova Announces CORE-VNS 24-Month Data Show Adjunctive VNS Therapy is Associated with Substantial Reductions in Generalized Tonic-Clonic Seizures in People with Drug-Resistant Epilepsy
LONDON--(BUSINESS WIRE)-- #epilepsy--LivaNova PLC announced CORE-VNS 24-month data show adjunctive VNS Therapy associated with substantial reduction in generalized tonic-clonic seizures.
LivaNova Initiates Process with U.S. Centers for Medicare and Medicaid Services for Reconsideration of National Coverage for VNS Therapy for Treatment-Resistant Depression
LONDON--(BUSINESS WIRE)-- #depression--LivaNova PLC announced it initiated the process with U.S. CMS to seek reconsideration of national Medicare coverage for VNS Therapy in depression.
LivaNova to Present at the Jefferies Global Healthcare Conference
LONDON--(BUSINESS WIRE)-- #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced Vladimir Makatsaria, Chief Executive Officer, will participate in a fireside c...